| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/04/2003 | CA2253490C Use of il-12 and ifn-.alpha. for the treatment of infectious diseases |
| 02/04/2003 | CA2205405C Method for treating secondary immunodeficiency |
| 02/04/2003 | CA2171953C Modified truncated complement system regulators |
| 02/04/2003 | CA2063810C Production of vascular endothelial cell growth factor |
| 02/04/2003 | CA2060325C Polypeptides with a dopaminergic receptor activity; nucleic acids coding for these polypeptides and use of the latter for screening active substances on said polypeptides |
| 02/04/2003 | CA2057313C Method of producing pathogen-resistant plants |
| 02/03/2003 | WO2002016548A2 Novel g protein-coupled receptor |
| 02/03/2003 | CA2418130A1 Novel g protein-coupled receptor |
| 01/30/2003 | WO2003008649A1 Methods and compositions relating to hpv-associated pre-cancerous and cancerous growths, including cin |
| 01/30/2003 | WO2003008640A2 Asthma-associated gene |
| 01/30/2003 | WO2003008628A2 Enzymatic nucleic acid peptide conjugates |
| 01/30/2003 | WO2003008626A2 Novel human nucleic acids encoding a pantothenate kinase and methods of use |
| 01/30/2003 | WO2003008625A2 Structural and cytoskeleton-associated proteins |
| 01/30/2003 | WO2003008621A2 87144, human amino acid transporter family member and uses therefor |
| 01/30/2003 | WO2003008598A1 Isolated human secreted proteins, nucleic acid molecules encoding human secreted proteins, and uses thereof |
| 01/30/2003 | WO2003008595A2 Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression |
| 01/30/2003 | WO2003008589A1 Elk1 PHOSPHORYLATION-ASSOCIATED GENE |
| 01/30/2003 | WO2003008586A2 Engineering oncolytic viruses |
| 01/30/2003 | WO2003008580A1 Galectin-14 therapeutic molecule and uses thereof |
| 01/30/2003 | WO2003008579A2 Polynucleotides expressed in dendritic cells and polypeptides encoded thereby |
| 01/30/2003 | WO2003008578A2 Reagents and methods for identifying gene targets for treating cancer |
| 01/30/2003 | WO2003008576A2 Synthetic double stranded oligonucleotides for targeted inhibition of gene expression |
| 01/30/2003 | WO2003008574A1 Mutations in ion channels |
| 01/30/2003 | WO2003008573A2 Silencing of gene expression by sirna |
| 01/30/2003 | WO2003008567A1 The tumor angiogenesis inhibitory factor-expressed efficiently virus specifically proliferating in tumor cell and uses thereof |
| 01/30/2003 | WO2003008560A2 A novel g protein-coupled receptor, gave8 |
| 01/30/2003 | WO2003008549A2 Antisense modulation of glioma-associated oncogene-3 expression |
| 01/30/2003 | WO2003008548A2 Mouse farnesoid x receptor sequences for use in comparative pharmacology |
| 01/30/2003 | WO2003008545A2 Antisense modulation of glioma-associated oncogene-2 expression |
| 01/30/2003 | WO2003008544A2 Antisense modulation of transforming growth factor-beta 3 expression |
| 01/30/2003 | WO2003008543A2 Antisense modulation of bcl2-associated x protein expression |
| 01/30/2003 | WO2003008537A2 Epitope sequences |
| 01/30/2003 | WO2003008454A2 Glycoprotein vi fusion proteins |
| 01/30/2003 | WO2003008449A1 Ntb-a, a surface molecule involved in natural killer cells activity |
| 01/30/2003 | WO2003008448A2 Novel human proton-gated channels |
| 01/30/2003 | WO2003008445A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/30/2003 | WO2003008444A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008443A2 Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/30/2003 | WO2003008441A2 Moringa seed proteins |
| 01/30/2003 | WO2003008439A1 ANTIMICROBIAL COMPOSITIONS CONTAINING β-AMINO ACID OLIGOMERS |
| 01/30/2003 | WO2003008438A2 Cosmetic or dermatological use of peptides for promoting adhesion between skin cells |
| 01/30/2003 | WO2003008433A1 Antisense modulation of cd40 ligand expression |
| 01/30/2003 | WO2003008394A1 Novel chelating agents and conjugates thereof, their synthesis and use as diagnostic and therapeutic agents |
| 01/30/2003 | WO2003008380A1 Carboxylic acid derivatives |
| 01/30/2003 | WO2003008378A1 Dolastatin 10 derivatives |
| 01/30/2003 | WO2003008374A1 Inhibitors of the ice/ced-3 family of cysteine proteases |
| 01/30/2003 | WO2003008038A1 Electro-medical device for use with biologics |
| 01/30/2003 | WO2003008007A2 Device for regeneration of articular cartilage and other tissue |
| 01/30/2003 | WO2003007992A1 Remedies for brain ischemic diseases |
| 01/30/2003 | WO2003007989A1 Anti-microbial targeting chimeric pharmaceutical |
| 01/30/2003 | WO2003007984A1 Uv cross-linkable melt adhesives containing stabilizers |
| 01/30/2003 | WO2003007983A1 Pharmaceutical composition comprising factor vii polypeptides and factor xi polypeptides |
| 01/30/2003 | WO2003007982A1 Sustained release hgf hydrogel preparations |
| 01/30/2003 | WO2003007981A1 Methods of treating liver fibrosis |
| 01/30/2003 | WO2003007980A1 Phosphinate-peptide analogues as inhibitors of procollagen-c-proteinase (pcp) for treating fibrotic diseases |
| 01/30/2003 | WO2003007979A1 An anti-angiogenic state in mice and humans with retinal photorecptor cell degeneration |
| 01/30/2003 | WO2003007978A1 Alpha-fetoprotein peptides and uses thereof |
| 01/30/2003 | WO2003007976A1 High protein, bowman-birk inhibitor concentrate and process for its manufacture |
| 01/30/2003 | WO2003007945A1 Viral polymerase inhibitors |
| 01/30/2003 | WO2003007890A2 Tropomyosin isoforms, and diagnostic and therapeutic uses therefor |
| 01/30/2003 | WO2003007889A2 Therapeutic agents comprising pro-apoptotic proteins |
| 01/30/2003 | WO2003007882A2 Method of making bowman-birk inhibitor product |
| 01/30/2003 | WO2003007880A2 Inhibition of behab cleavage and primary central nervous system (cns) tumors |
| 01/30/2003 | WO2003007874A2 Anti-tumor activity from reptile serum |
| 01/30/2003 | WO2003007867A2 A salt/ion pair medicinal aerosol formulation |
| 01/30/2003 | WO2003007845A1 Dry hemostatic compositions and methods for their preparation |
| 01/30/2003 | WO2003007800A2 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer |
| 01/30/2003 | WO2003007794A2 Invasion complex and methods of targeting |
| 01/30/2003 | WO2003007793A2 Compositions, methods, and kits related to treating and diagnosing hypertension |
| 01/30/2003 | WO2003007733A1 Protein-containing foodstuff comprising a cross-linking enzyme and a hydrocolloid |
| 01/30/2003 | WO2003007689A2 Compositions and methods for use of bioactive agents derived from sulfated and sulfonated amino acids |
| 01/30/2003 | WO2003007686A2 Use of copper chelators to inhibit the inactivation of protein c |
| 01/30/2003 | WO2003000707A9 Antisense modulation of superoxide dismutase 1, soluble expression |
| 01/30/2003 | WO2002090986A9 Colon cancer antigen panel |
| 01/30/2003 | WO2002089817A3 Anti-virus agent |
| 01/30/2003 | WO2002087554A3 Ef-tu binding agent as antibacterial agent |
| 01/30/2003 | WO2002083167A3 Therapeutic compositions for the treatment of a respiratory tract disease |
| 01/30/2003 | WO2002079478A3 Modification of organelle metabolism by a composition comprising unc-51-like kinases, roma1, or 2tm polypeptides and uses thereof for the preration of a medicament for the treatment disorders |
| 01/30/2003 | WO2002070538A9 Narc8 programmed cell-death-associated molecules and uses thereof |
| 01/30/2003 | WO2002068585A9 Tip39 polypeptides |
| 01/30/2003 | WO2002066623A3 Regulation of human phosphatidic acid-preferring phospholipase a1 |
| 01/30/2003 | WO2002066500A3 ANTAGONISTS FPR Α4β7-INTEGRIN |
| 01/30/2003 | WO2002064160A8 Pharmaceutical compositions which inhibit vascular proliferation and method of use thereof |
| 01/30/2003 | WO2002060917A3 Method to treat hemophilia |
| 01/30/2003 | WO2002059337A9 Anti-apoptopic gene scc-s2 and diagnostic and therapeutic uses thereof |
| 01/30/2003 | WO2002055101A3 Storage stable powder compositions of interleukin-4 receptor |
| 01/30/2003 | WO2002051435A3 New therapeutic uses of smr1 peptides |
| 01/30/2003 | WO2002048180A3 Peptides and/or proteins and use thereof for the production of a therapeutic and/or prophylactic medicament |
| 01/30/2003 | WO2002047715A3 Compositions of peptide crystals |
| 01/30/2003 | WO2002042423A3 Antisense modulation of src-2 expression |
| 01/30/2003 | WO2002036166A3 Compositions for stimulating cd45 and thereby suppressing microglial activation associated with alzheimer's disease |
| 01/30/2003 | WO2002036154A3 Procollagen (iii) propeptides and related substances for treating fibrotic diseases |
| 01/30/2003 | WO2002034243A3 Method for the treatment of neurological and neuropsychological disorders |
| 01/30/2003 | WO2002034242A3 Method for the treatment of neurological and neuropsychological disorders |
| 01/30/2003 | WO2002033115A3 Claspin proteins and methods of use thereof |
| 01/30/2003 | WO2002031143A3 Nucleic acid sequences encoding cmg proteins cmg proteins and methods for their use |
| 01/30/2003 | WO2002026988A3 Human drug metabolizing enzymes |
| 01/30/2003 | WO2002026215A3 Thermogelling biodegradable aqueous polymer solution |
| 01/30/2003 | WO2002020763A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 01/30/2003 | WO2002018583A3 Modified polypeptides stabilized in a desired conformation and methods for producing same |